CONSHOHOCKEN, PA — Madrigal Pharmaceuticals (Nasdaq: MDGL) will report its second-quarter 2026 financial results on July 30 before U.S. markets open, giving investors an updated view of the commercial performance of Rezdiffra, the company’s approved treatment for metabolic dysfunction-associated steatohepatitis (MASH), and its broader development pipeline.
The company stated it will host a live webcast at 8 a.m. Eastern Time following the earnings release to discuss its financial and operating results. A replay will be available about two hours after the live event through the investor relations section of the company’s website.
The quarterly report comes as investors continue to monitor the commercial trajectory of Rezdiffra, which became the first therapy approved by both the U.S. Food and Drug Administration and the European Commission for adults with MASH and moderate to advanced liver fibrosis (stages F2 to F3).
Beyond current sales, market attention remains focused on Madrigal’s ongoing Phase 3 outcomes study evaluating Rezdiffra in patients with compensated MASH cirrhosis (F4c). Positive results could expand the drug’s addressable patient population and strengthen the company’s position in a growing market for treatments targeting chronic liver disease.
Participants planning to join the earnings webcast are encouraged to register before the scheduled start time. The webcast and replay will be available through the investor relations section of Madrigal Pharmaceuticals’ website.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.